Vitiligo Emerging and Marketed Drugs Assessment, (2023 Updates) | Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, Competitive Landscape, and Key Companies

March 13 20:54 2023
Vitiligo Emerging and Marketed Drugs Assessment, (2023 Updates) | Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, Competitive Landscape, and Key Companies
Delveinsight Business Research LLP
As per DelveInsight’s assessment, about 22+ key pharma and biotech companies are working on 22+ pipeline drugs in the Vitiligo therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

As per DelveInsight, the Vitiligo therapeutics market is anticipated to grow in the coming years owing to the rise in the number of prevalent cases of Vitiligo, the rise in healthcare spending across the world, and the expected launch of drugs in the market. Some of the key companies in the Vitiligo therapeutics market include ICN Pharmaceuticals, Inc, Valeant Pharmaceuticals, Astellas Pharma, and others.

Vitiligo Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Vitiligo Market. 

The Vitiligo Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Vitiligo Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for the treatment of Vitiligo and the aggregate therapies developed by major pharma companies.

  • It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Vitiligo market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Analysis of Emerging Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

Route of Administration

Vitiligo pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

  • Oral

  • Parenteral

  • Intravitreal

  • Subretinal

  • Topical

Molecule Type

The emerging pipeline products have been categorized under various Molecule types in the report, such as –

  • Monoclonal Antibody

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy

Mechanism of Action of the Emerging Pipeline Therapies

  • Janus kinase 1 inhibitor

  • Emt protein-tyrosine kinase inhibitors

  • TYK2 kinase inhibitors

  • Syk kinase inhibitors

  • Interleukin 15 inhibitors

  • HSP70 heat shock protein stimulants

  • IFN-γ antagonist

  • Melanocortin type 1 receptor modulators

Learn How the Ongoing Clinical & Commercial Activities will Affect the Vitiligo Therapeutic Segment @

Leading Companies in the Vitiligo Therapeutics Market Include:

  • Aclaris Therapeutics

  • Amgen

  • Arcutis Biotherapeutics

  • Arrien Pharmaceuticals

  • AXIM Biotechnologies

  • Bioniz Therapeutics

  • Boston Pharmaceuticals

  • Celgene

  • Clinuvel Pharmaceuticals

  • Dermavant Sciences

  • Incyte Corporation

  • Pfizer

  • Temprian Therapeutics

  • TWi Biotechnology

And Many Others

Vitiligo Emerging and Marketed Drugs Covered in the Report Include:

  • 1BNZ-1: Bioniz Therapeutics

  • AC-1101: TWi Biotechnology

  • Afamelanotide: Clinuvel, Inc.

  • AMG-714: Amgen

  • ATI-1777: Aclaris Therapeutics

  • Cerdulatinib: Dermavant Sciences

  • PF-06651600: Pfizer

  • Phimelanotide – Clinuvel Pharmaceuticals

  • Ritlecitinib: Pfizer

  • Ruxolitinib: Incyte Corporation

  • TT-01: Temprian Therapeutics

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Vitiligo Current Treatment Patterns

4. Vitiligo – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Vitiligo Late Stage Products (Phase-III)

7. Vitiligo Mid-Stage Products (Phase-II)

8. Vitiligo Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Vitiligo Discontinued Products

13. Vitiligo Product Profiles

14. Key Companies in the Vitiligo Market

15. Key Products in the Vitiligo Therapeutics Segment

16. Dormant and Discontinued Products

17. Vitiligo Unmet Needs

18. Vitiligo Future Perspectives

19. Vitiligo Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @


Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic and evolving pharmaceutical market today @ Pharmaceutical Partner Identification Services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States